Results 281 to 290 of about 1,127,554 (354)

Neoadjuvant chemotherapy for early-stage colon cancer.

Cancer Treatment Reviews, 2023
Surgery with or without adjuvant chemotherapy is the standard treatment for early-stage colon cancer. However, evidence has recently emerged for neoadjuvant chemotherapy, with the results of randomised clinical trials sparking debates within ...
A. Audisio, R. Fazio, V. Daprà, Irene Assaf, A. Hendlisz, Francesco Sclafani   +5 more
semanticscholar   +1 more source

Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)

Annals of Surgery, 2022
Objective: Given the frequent adverse events with multidrug chemotherapy, not only the survival benefit but also the feasibility of using neoadjuvant chemotherapy to treat pancreatic cancer need to be clarified.
J. Yamaguchi, Y. Yokoyama, T. Fujii, S. Yamada, H. Takami, H. Kawashima, E. Ohno, T. Ishikawa, O. Maeda, H. Ogawa, Y. Kodera, M. Nagino, T. Ebata   +12 more
semanticscholar   +1 more source

Neoadjuvant Chemotherapy in Pancreatic Cancer

JAMA Surgery, 2021
There is increasing interest in the use of adjuvant treatment for pancreatic cancer since although postoperative mortality is much improved, median long-term survival is only on the order of 11–15 mo. Despite a proliferation of studies in advanced pancreatic cancer indicating a benefit for chemotherapy, there has only been one small randomized adjuvant
Thomas, Hank, Markus W, Büchler, John P, Neoptolemos   +2 more
openaire   +4 more sources

Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy

EBioMedicine, 2021
Background Recent evidence shows that inducing ferroptosis may improve efficacy of tumor therapy. However, ferroptosis-related genes have been little studied in patients with breast cancer especially in the neoadjuvant setting.
Rui Sha, Yaqian Xu, Chenwei Yuan, Xiaonan Sheng, Ziping Wu, Jing Peng, Yaohui Wang, Yanping Lin, Liheng Zhou, Shuguang Xu, J. Zhang, W. Yin, Jinsong Lu   +12 more
semanticscholar   +1 more source

Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).

International Journal of Surgery, 2022
BACKGROUND Clinical benefit of neoadjuvant immunotherapy in resectable esophageal squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and safety of the programmed death 1 (PD-1) inhibitor tislelizumab combined with ...
Xiaolong Yan, Hongtao Duan, Yun-feng Ni, Yong’an Zhou, Xiaoping Wang, Haini Qi, L. Gong, Honggang Liu, F. Tian, Q. Lu, Jianyong Sun, E. Yang, D. Zhong, Tao Wang, Lijun Huang, Jian Wang, chaoyang Wang, Yuanyong Wang, Zhiyi Wan, J. Lei, Jinbo Zhao, T. Jiang   +21 more
semanticscholar   +1 more source